CN101374414A - 用于治疗代谢紊乱的化合物 - Google Patents

用于治疗代谢紊乱的化合物 Download PDF

Info

Publication number
CN101374414A
CN101374414A CNA2007800035189A CN200780003518A CN101374414A CN 101374414 A CN101374414 A CN 101374414A CN A2007800035189 A CNA2007800035189 A CN A2007800035189A CN 200780003518 A CN200780003518 A CN 200780003518A CN 101374414 A CN101374414 A CN 101374414A
Authority
CN
China
Prior art keywords
carbon atoms
compound
group
formula
reaction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2007800035189A
Other languages
English (en)
Chinese (zh)
Inventor
沙林·夏尔马
里德·W·冯博斯特尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wellstat Therapeutics Corp
Original Assignee
Wellstat Therapeutics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellstat Therapeutics Corp filed Critical Wellstat Therapeutics Corp
Publication of CN101374414A publication Critical patent/CN101374414A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/32—Oxygen atoms
    • C07D307/33—Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N35/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having two bonds to hetero atoms with at the most one bond to halogen, e.g. aldehyde radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Agronomy & Crop Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Plant Pathology (AREA)
  • Dentistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CNA2007800035189A 2006-01-25 2007-01-22 用于治疗代谢紊乱的化合物 Pending CN101374414A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US76206606P 2006-01-25 2006-01-25
US60/762,066 2006-01-25

Publications (1)

Publication Number Publication Date
CN101374414A true CN101374414A (zh) 2009-02-25

Family

ID=38309904

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2007800035189A Pending CN101374414A (zh) 2006-01-25 2007-01-22 用于治疗代谢紊乱的化合物

Country Status (11)

Country Link
US (1) US7915429B2 (enExample)
EP (1) EP1976510A4 (enExample)
JP (1) JP2009524686A (enExample)
KR (1) KR20080089453A (enExample)
CN (1) CN101374414A (enExample)
AU (1) AU2007208125B2 (enExample)
CA (1) CA2637373A1 (enExample)
IL (1) IL192851A0 (enExample)
NZ (1) NZ569728A (enExample)
WO (1) WO2007087504A2 (enExample)
ZA (1) ZA200805595B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103796994A (zh) * 2011-06-23 2014-05-14 马特波利公司 哌嗪类衍生物及其制备方法以及在治疗胰岛素抵抗中的应用

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0407506A (pt) * 2003-02-13 2006-02-14 Wellstat Therapeutics Corp compostos para o tratamento de distúrbios metabólicos, seu uso e composição farmacêutica compreendendo os mesmos
AU2004237602B2 (en) * 2003-04-30 2009-05-28 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
AU2007212104A1 (en) * 2006-02-02 2007-08-16 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
US8481595B2 (en) * 2008-01-15 2013-07-09 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1561350A (en) 1976-11-05 1980-02-20 May & Baker Ltd Benzamide derivatives
US4663478A (en) 1984-02-14 1987-05-05 Hidefuni Hirai Process for producing a para-substituted phenol derivative
EP0279630B1 (en) 1987-02-16 1993-10-13 Konica Corporation Developer for light-sensitive lithographic printing plate capable of processing commonly the negative-type and the positive type and developer composition for light-sensitive material
JPH064544B2 (ja) 1987-06-19 1994-01-19 高砂香料工業株式会社 光学活性アルコ−ルの製造方法
JPH0770025B2 (ja) 1987-09-16 1995-07-31 富士通株式会社 薄膜磁気ヘッドの製造方法
US4923501A (en) 1987-11-04 1990-05-08 Kumiai Chemical Industry Co., Ltd. Pyrimidine derivatives, processes for their production, and herbicidal method and compositions
JPH04154773A (ja) 1990-10-15 1992-05-27 Green Cross Corp:The チアゾール誘導体
JPH04282345A (ja) 1991-03-11 1992-10-07 Mitsubishi Petrochem Co Ltd 光学活性化合物
JPH08501100A (ja) 1992-09-09 1996-02-06 イー・アイ・デユポン・ドウ・ヌムール・アンド・カンパニー 除草性ベンゼン化合物
US5484926A (en) 1993-10-07 1996-01-16 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
JPH06293700A (ja) 1993-04-08 1994-10-21 Nippon Soda Co Ltd ６−クロロサリチル酸の製造法
GB9315595D0 (en) 1993-07-28 1993-09-08 Res Inst Medicine Chem New compounds
JPH07206658A (ja) 1994-01-12 1995-08-08 Shiseido Co Ltd 尋常性座瘡治療剤
JPH08119959A (ja) 1994-10-20 1996-05-14 Oyo Seikagaku Kenkyusho キサントン誘導体及びこれを有効成分とするモノアミン酸化酵素阻害剤
US5728718A (en) 1994-12-20 1998-03-17 The United States Of America As Represented By The Department Of Health And Human Services 2,5-diamino-3,4-disubstituted-1,6-diphenylhexane isosteres comprising benzamide, sulfonamide and anthranilamide subunits and methods of using same
FR2730731B1 (fr) 1995-02-20 1997-04-04 Rhone Poulenc Chimie Procede de carboxylation d'un ether aromatique
AU4953796A (en) 1995-03-15 1996-10-02 Sanyko Company, Limited Dipeptide compounds having ahpba structure
US5519133A (en) 1995-06-02 1996-05-21 American Cyanamid Co. 3-(3-aryloxyphenyl)-1-(substituted methyl)-s-triazine-2,4,6-oxo or thiotrione herbicidal agents
US6194406B1 (en) 1995-12-20 2001-02-27 Aventis Pharmaceuticals Inc. Substituted 4-(1H-benzimidazol-2-yl)[1,4]diazepanes useful for the treatment of allergic disease
US6423704B2 (en) 1995-12-20 2002-07-23 Aventis Pharmaceuticals Inc. Substituted 4-(1H-benzimidazol-2-yl)[1,4]diazepanes useful for the treatment of allergic diseases
WO1997025992A1 (en) 1996-01-16 1997-07-24 Merck & Co., Inc. Tocolytic oxytocin receptor antagonists
US6297274B1 (en) * 1996-04-10 2001-10-02 Warner-Lambert Company Nonpeptide endothelin antagonists with increased water solubility
DE19617864A1 (de) * 1996-04-23 1997-10-30 Schering Ag Neue chirale Phenyldihydrofuranone
WO1997045400A1 (en) 1996-05-24 1997-12-04 Neurosearch A/S Phenyl derivatives containing an acidic group, their preparation and their use as chloride channel blockers
JPH1087489A (ja) 1996-09-13 1998-04-07 Sankyo Co Ltd Ａｈｐｂａ構造含有ジペプチド化合物を有効成分とする医薬
WO1998017788A1 (en) * 1996-10-22 1998-04-30 Daicel Chemical Industries, Ltd. Novel secondary alcohol dehydrogenase, process for preparing said enzyme, and process for preparing alcohols and ketones using said enzyme
CA2302009A1 (en) 1997-09-09 1999-03-18 Merck & Co., Inc. 3-(iodophenoxymethyl) carbapenem antibacterials
KR20010015639A (ko) 1997-09-30 2001-02-26 스즈키 다다시 술포닐 유도체
US6255498B1 (en) * 1998-10-16 2001-07-03 Millennium Pharmaceuticals, Inc. Method for synthesizing diaryl-substituted heterocyclic compounds, including tetrahydrofurans
GB9914371D0 (en) 1999-06-18 1999-08-18 Smithkline Beecham Plc Novel compounds
CZ302982B6 (cs) 2000-06-28 2012-02-01 Amgen Inc. 3-Chinolinylfenylsulfonamidová sloucenina, tato sloucenina pro použití jako lécivo a použití této slouceniny pri výrobe léciva
AR031126A1 (es) 2000-08-29 2003-09-10 Abbott Lab Acidos amino(oxo)aceticos inhibidores de la proteina tirosina fosfatasa
AR035216A1 (es) 2000-12-01 2004-05-05 Astrazeneca Ab Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios
MXPA03011558A (es) 2001-06-12 2004-03-26 Wellstat Therapeutics Corp Compuestos para el tratamiento de desordenes metabolicos.
US20040092529A1 (en) * 2002-10-30 2004-05-13 Pfizer Inc Methods of using piperazine derivatives
WO2004041165A2 (en) 2002-11-01 2004-05-21 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
BRPI0407506A (pt) 2003-02-13 2006-02-14 Wellstat Therapeutics Corp compostos para o tratamento de distúrbios metabólicos, seu uso e composição farmacêutica compreendendo os mesmos
PL1633340T3 (pl) 2003-04-15 2011-04-29 Wellstat Therapeutics Corp Związki do leczenia chorób metabolicznych
CN1777576A (zh) 2003-04-22 2006-05-24 维尔斯达医疗公司 用于治疗代谢紊乱的化合物
AU2004237602B2 (en) 2003-04-30 2009-05-28 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
WO2005018628A1 (en) 2003-08-20 2005-03-03 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103796994A (zh) * 2011-06-23 2014-05-14 马特波利公司 哌嗪类衍生物及其制备方法以及在治疗胰岛素抵抗中的应用
US9150529B2 (en) 2011-06-23 2015-10-06 Metabolys Piperazine derivatives, methods for preparing same, and uses thereof in the treatment of insulin resistance
CN103796994B (zh) * 2011-06-23 2015-11-25 马特波利公司 哌嗪类衍生物及其制备方法以及在治疗胰岛素抵抗中的应用

Also Published As

Publication number Publication date
WO2007087504A2 (en) 2007-08-02
NZ569728A (en) 2010-11-26
KR20080089453A (ko) 2008-10-06
WO2007087504A3 (en) 2007-11-15
US7915429B2 (en) 2011-03-29
IL192851A0 (en) 2009-02-11
EP1976510A2 (en) 2008-10-08
US20080319049A1 (en) 2008-12-25
AU2007208125A1 (en) 2007-08-02
AU2007208125B2 (en) 2012-04-05
ZA200805595B (en) 2009-10-28
JP2009524686A (ja) 2009-07-02
EP1976510A4 (en) 2010-06-09
CA2637373A1 (en) 2007-08-02

Similar Documents

Publication Publication Date Title
EP1988772B1 (en) Compounds for the treatment of metabolic disorders
US7820721B2 (en) Compounds for the treatment of metabolic disorders
US7935689B2 (en) Compounds for the treatment of metabolic disorders
US7973052B2 (en) Compounds for the treatment of metabolic disorders
US7947735B2 (en) Compounds for the treatment of metabolic disorders
CN101374414A (zh) 用于治疗代谢紊乱的化合物
CN101378740A (zh) 用于治疗代谢紊乱的化合物
MX2008009594A (en) Compounds for the treatment of metabolic disorders

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20090225